药物性肝损伤的发病机制研究进展
Advances in the Pathogenesis of Drug-Induced Liver Injury
DOI: 10.12677/PI.2022.113022, PDF,   
作者: 焦军霞：山东大学附属公共卫生临床中心，山东 济南
关键词: 药物性肝损伤；发病机制；药物治疗；Drug-Induced Liver Injury； Pathogenesis； Drug Therapy
摘要: 药物性肝损伤(DILI)是最常见和最严重的药物不良反应之一，所涉及药物种类复杂，其发生机制尚不十分明确，治疗暂无特效药。本文对DILI的发病机制的相关研究进行综述，以期为DILI的药物治疗提供依据。
Abstract: Drug-induced Liver Injury (DILI) is one of the most common and serious adverse drug reactions. The types of drugs involved in DILI are complex and the mechanism is not completely clear. There is no specific drug for the treatment of IDIL. In this review, the related researches on the pathogenesis of DILI are briefly reviewed in order to provide evidence for drug treatment of DILI.
文章引用：焦军霞. 药物性肝损伤的发病机制研究进展[J]. 药物资讯, 2022, 11(3): 182-188. https://doi.org/10.12677/PI.2022.113022

参考文献

[1] Chalasani, N.P., Maddur, H., Russo, M.W., Wong, R.J. and Reddy, K.R. (2021) ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. The American Journal of Gastroenterology, 116, 878-898. [Google Scholar] [CrossRef] [PubMed]
[2] Björnsson, E.S. (2014) Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury. Seminars in Liver Disease, 34, 115-122. [Google Scholar] [CrossRef] [PubMed]
[3] Björnsson, E., Jerlstad, P., Bergqvist, A. and Olsson, R. (2005) Ful-minant Drug-Induced Hepatic Failure Leading to Death or Liver Transplantation in Sweden. Scandinavian Journal of Gastroenterology, 40, 1095-1101. [Google Scholar] [CrossRef] [PubMed]
[4] Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P.B., Aithal, G.P., Andrade, R.J., Dou, X., Yao, L., Lv, F., Wang, Q., Li, Y., Zhou, X., Zhang, Y., Zong, P., Wan, B., Zou, Z., Yang, D., Nie, Y., Li, D., Wang, Y., Han, X., Zhuang, H., Mao, Y. and Chen, C. (2019) In-cidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology, 156, 2230-2241.e11. [Google Scholar] [CrossRef] [PubMed]
[5] Roth, R.A. and Ganey, P.E. (2010) Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity—Two Villains or One? Journal of Pharmacology and Experimental Therapeutics, 332, 692-697. [Google Scholar] [CrossRef] [PubMed]
[6] Zou, M., Wang, A., Wei, J., Cai, H., Yu, Z., Zhang, L. and Wang, X. (2021) An Insight into the Mechanism and Molecular Basis of Dysfunctional Immune Response Involved in Cholestasis. International Immunopharmacology, 92, Article ID: 107328. [Google Scholar] [CrossRef] [PubMed]
[7] Thompson, R.A., Isin, E.M., Ogese, M.O., Mettetal, J.T. and Williams, D.P. (2016) Reactive Metabolites: Current and Emerging Risk and Hazard Assessments. Chemical Research in Toxicology, 29, 505-533. [Google Scholar] [CrossRef] [PubMed]
[8] Lynch, T. and Price, A. (2007) The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects. American Family Physician, 76, 391-396.
[9] Kim, S.H. and Naisbitt, D.J. (2016) Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy, Asthma & Immunology Research, 8, 3-11. [Google Scholar] [CrossRef] [PubMed]
[10] Martin-Murphy, B.V., Holt, M.P. and Ju, C. (2010) The Role of Damage Associated Molecular Pattern Molecules in Acetaminophen-Induced Liver Injury in Mice. Toxicology Letters, 192, 387-394. [Google Scholar] [CrossRef] [PubMed]
[11] Uetrecht, J. (2007) Idiosyncratic Drug Reactions: Current Under-standing. Annual Review of Pharmacology and Toxicology, 47, 513-539. [Google Scholar] [CrossRef] [PubMed]
[12] Papay, J.I., Clines, D., Rafi, R., Yuen, N., Britt, S.D., Walsh, J.S. and Hunt, C.M. (2009) Drug-Induced Liver Injury Following Positive Drug Rechallenge. Regulatory Toxicology and Pharmacology, 54, 84-90. [Google Scholar] [CrossRef] [PubMed]
[13] Foureau, D.M., Walling, T.L., Maddukuri, V. anderson, W., Cul-breath, K., Kleiner, D.E., Ahrens, W.A., Jacobs, C., Watkins, P.B., Fontana, R.J., Chalasani, N., Talwalkar, J., Lee, W.M., Stolz, A., Serrano, J. and Bonkovsky, H.L. (2015) Comparative Analysis of Portal Hepatic Infiltrating Leucocytes in Acute Drug-Induced Liver Injury, Idiopathic Autoimmune and Viral Hepatitis. Clinical & Experimental Immunology, 180, 40-51. [Google Scholar] [CrossRef] [PubMed]
[14] Whritenour, J., Ko, M., Zong, Q., Wang, J., Tartaro, K., Schneider, P., Olson, E., Van Volkenburg, M., Serrano, J., Hayashi, P., Fontana, R., Chalasani, N. and Bonkovsky, H.L. (2017) Development of a Modified Lymphocyte Transformation Test for Diagnosing Drug-Induced Liver Injury Associ-ated with an Adaptive Immune Response. Journal of Immunotoxicology, 14, 31-38. [Google Scholar] [CrossRef] 
[15] Cacabelos, R., Cacabelos, N. and Carril, J.C. (2019) The Role of Pharmacogenomics in Adverse Drug Reactions. Expert Review of Clinical Pharmacology, 12, 407-442. [Google Scholar] [CrossRef] [PubMed]
[16] Osanlou, O., Pirmohamed, M. and Daly, A.K. (2018) Phar-macogenetics of Adverse Drug Reactions. Advances in Pharmacology, 83, 155-190. [Google Scholar] [CrossRef] [PubMed]
[17] Mallal, S., Phillips, E., Carosi, G., Molina, J.M., Workman, C., Tomazic, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J.F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D., Benbow, A. and PREDICT-1 Study Team (2008) HLA-B*5701 Screening for Hypersensitivity to Abacavir. The New England Journal of Medicine, 358, 568-579. [Google Scholar] [CrossRef] 
[18] Chipinda, I., Hettick, J.M. and Siegel, P.D. (2011) Haptenation: Chemical Reactivity and Protein Binding. Journal of Allergy (Cairo), 2011, Article ID: 839682. [Google Scholar] [CrossRef] [PubMed]
[19] Matzinger, P. (1994) Tolerance, Danger, and the Extended Family. An-nual Review of Immunology, 12, 991-1045. [Google Scholar] [CrossRef] [PubMed]
[20] Banoth, B. and Cassel, S.L. (2018) Mitochondria in In-nate Immune Signaling. Translational Research, 202, 52-68. [Google Scholar] [CrossRef] [PubMed]
[21] Stewart, J.D., Horvath, R., Baruffini, E., Ferrero, I., Bulst, S., Wat-kins, P.B., Fontana, R.J., Day, C.P. and Chinnery, P.F. (2010) Polymerase γ Gene POLG Determines the Risk of Sodi-um Valproate-Induced Liver Toxicity. Hepatology, 52, 1791-1796. [Google Scholar] [CrossRef] [PubMed]
[22] Dykens, J.A. and Will, Y. (2007) The Significance of Mitochondrial Toxicity Testing in Drug Development. Drug Discovery To-day, 12, 777-785. [Google Scholar] [CrossRef] [PubMed]
[23] Morgan, R.E., van Staden, C.J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R.T., Afshari, C.A. and Hamadeh, H.K. (2013) A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development. Toxicological Sciences, 136, 216-241. [Google Scholar] [CrossRef] [PubMed]
[24] Eyraud, D. (2015) Clinics and Research in Hepatology and Gastroenterology. Clinics and Research in Hepatology and Gastroenterology, 39, 151-152. [Google Scholar] [CrossRef] [PubMed]
[25] Kleiner, D.E., Chalasani, N.P., Lee, W.M., Fontana, R.J., Bonkovsky, H.L., Watkins, P.B., Hayashi, P., Davern, T.J., Navarro, V., Reddy, R., Talwalkar, J.A., Stolz, A., Gu, J., Barnhart, H. and Hoofnagle, J.H. (2014) Drug-Induced Liver Injury Network (DILIN). Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations. Hepatology, 59, 661-670. [Google Scholar] [CrossRef] [PubMed]
[26] Roth, R.A., Luyendyk, J.P., Maddox, J.F. and Ganey, P.E. (2003) Inflam-mation and Drug Idiosyncrasy—Is There a Connection? Journal of Pharmacology and Experimental Therapeutics, 307, 1-8. [Google Scholar] [CrossRef] [PubMed]
[27] Massart, J., Begriche, K., Moreau, C. and Fromenty, B. (2017) Role of Nonalcoholic Fatty Liver Disease as Risk Factor for Drug-Induced Hepatotoxicity. Journal of Clinical and Transla-tional Research, 3, 212-232.
[28] Thaiss, C.A., Zmora, N., Levy, M. and Elinav, E. (2016) The Microbiome and Innate Immunity. Nature, 535, 65-74. [Google Scholar] [CrossRef] [PubMed]
[29] Chowdhury, N.I., Remington, G., Kennedy, J.L. (2011) Genetics of An-tipsychotic-Induced Side Effects and Agranulocytosis. Current Psychiatry Reports, 13, 156-165. [Google Scholar] [CrossRef] [PubMed]
[30] Ng, W., Kennar, R. and Uetrecht, J. (2014) Effect of Clozapine and Olanzapine on Neutrophil Kinetics: Implications for Drug-Induced Agranulocytosis. Chemical Research in Toxicol-ogy, 27, 1104-1108. [Google Scholar] [CrossRef] [PubMed]
[31] Lee, T., Lee, Y.S., Yoon, S.Y., Kim, S., Bae, Y.J., Kwon, H.S., Cho, Y.S., Moon, H.B. and Kim, T.B. (2013) Characteristics of Liver Injury in Drug-Induced Systemic Hypersensitivity Reactions. Journal of the American Academy of Dermatology, 69, 407-415. [Google Scholar] [CrossRef] [PubMed]
[32] Stine, J.G. and Lewis, J.H. (2016) Current and Future Directions in the Treatment and Prevention of Drug-Induced Liver Injury: A Systematic Review. Expert Review of Gastroenterology & Hepatology, 10, 517-536. [Google Scholar] [CrossRef] [PubMed]
[33] Law, E.H. and Leung, M. (2015) Corticosteroids in Ste-vens-Johnson Syndrome/Toxic Epidermal Necrolysis: Current Evidence and Implications for Future Research. Annals of Pharmacotherapy, 49, 335-342. [Google Scholar] [CrossRef] [PubMed]
[34] Valeyrie-Allanore, L., Wolkenstein, P., Brochard, L., Ortonne, N., Maître, B., Revuz, J., Bagot, M. and Roujeau, J.C. (2010) Open Trial of Ciclosporin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. British Journal of Dermatology, 163, 847-853. [Google Scholar] [CrossRef] [PubMed]
[35] Young, N.S. (2013) Current Concepts in the Pathophysi-ology and Treatment of Aplastic Anemia. Hematology: The American Society of Hematology Education Program, 2013, 76-81. [Google Scholar] [CrossRef] [PubMed]